RXRX Healthcare

Recursion Pharmaceuticals, Inc.

$3.68-3.92%

Price as of close on Nov 3, 2026 · Financials updated Sep 30, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 2.0B USD
Enterprise value: 1.3B USD
Full-time employees: 600

Overall health

Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity
Drawback: less profitable than most peersless profitable than peers
Drawback: growing more slowly than most peersgrowing more slowly than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: its share price swings more than most peers’ (beta 1.07 vs a peer median of 0.63)bigger price swings (beta 1.07 vs peers 0.63)

Ranks #1,063 of 1,157 healthcare companies (bottom 9%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 180% from December 2022 to July 2026.
Recursion Pharmaceuticals had 180% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Recursion Pharmaceuticals had 180% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Stock-based pay is a large cost. Stock pay was 149% of revenue in 2025.
Recursion Pharmaceuticals paid employees $111M in stock in 2025, 149% of its $75M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Recursion Pharmaceuticals looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to June 2026.
Recursion Pharmaceuticals reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

StockQuotient Score

24/ 100

Oct 5 24 → Nov 4 24

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-26.3%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-32.4%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-17.9%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield46.4%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

17/100

Weak

2/3 inputs reported · Partial data

Since last quarter: ▼ Weaker

12-month revenue fell 17.4%

Why

Weaker than most peers on:

▼ Revenue growth
▼ 3-yr revenue

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0976 · MAD: 0.2991

3-year revenue growth3.1%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score -0.32Sector median: 0.0584 · MAD: 0.0840

Revenue growth-15.1%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -2.17Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

3/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Operating margin
▼ ROIC
▼ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-991.7%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -71.87Sector median: 0.0706 · MAD: 0.1217

Return on assets-42.8%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -8.28Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-112.1%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -11.63Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin3.5%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-56.7%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Debt / equity
▲ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.07

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -1.32Sector median: 0.6250 · MAD: 0.3380

Current ratio5.03×

SEC filings · latest balance sheetReported value33% base weight · Z-score 1.77Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.02×

SEC filings · latest balance sheetReported value33% base weight · Z-score 1.01Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Recursion Pharmaceuticals

Is Recursion Pharmaceuticals getting weaker?: Its latest SEC filing (Aug 5, 2026) got weaker in some ways: 12-month revenue fell 17.4%. Its overall score is unchanged at 24/100 since Oct 28, 2026.
How is Recursion Pharmaceuticals valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -26.3% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -26.3% vs peers 1.5% (weaker than 100% of peers).
Is Recursion Pharmaceuticals growing?: More slowly than most of its peers. Growth scores 17/100 against 1,393 healthcare peers. Revenue growth -15.1% vs a peer median of 6.1% (weaker than 88% of peers).Revenue growth -15.1% vs peers 6.1% (weaker than 88% of peers).
How profitable is Recursion Pharmaceuticals?: Less profitable than most of its peers. Profitability scores 3/100 against 1,393 healthcare peers. Operating margin -991.7% vs a peer median of 7.1% (weaker than 100% of peers).Operating margin -991.7% vs peers 7.1% (weaker than 100% of peers).
How risky is Recursion Pharmaceuticals?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.02× vs a peer median of 0.22× (stronger than 87% of peers).Debt / equity 0.02× vs peers 0.22× (stronger than 87% of peers). Beta 1.07 vs a peer median of 0.63 (weaker than 74% of peers).Beta 1.07 vs peers 0.63 (weaker than 74% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 5, 2026 · compared with the quarter ended Mar 31, 2026

Got weaker

12-month revenue fell 17.4%

Worth watching: Recursion Pharmaceuticals is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Revenue (12 months)	66.4M USD	54.9M USD	−17.4%
Net income (12 months)	−559.8M USD	−518.9M USD	−7.3%
Operating margin	-881.3%	-991.7%	−110.4 pts
Free cash flow (12 months)	−325.8M USD	−352.3M USD	+8.1%
Debt	16.4M USD	14.2M USD	−13.7%
Cash	654.5M USD	545.7M USD	−16.6%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	100.0%	-21.2%	4.5%	23.1%	5.0%	▼ 18 pts
Operating margin	-1795.8%	-616.7%	-785.3%	-814.1%	-867.9%	▼ 54 pts
Net margin	-1832.2%	-601.0%	-736.0%	-788.0%	-863.4%	▼ 75 pts
Return on assets (ROA)	-30.6%	-34.1%	-50.2%	-32.0%	-43.7%	▼ 12 pts
Return on equity (ROE)	-34.3%	-49.3%	-70.8%	-44.8%	-57.0%	▼ 12 pts
Free cash flow margin	-1949.4%	-302.6%	-672.4%	-633.7%	-506.5%	▲ 127 pts
Current ratio	11.46×	5.68×	4.70×	3.81×	5.50×	▲ 44%
Debt to equity	0.00×	0.00×	0.00×	0.03×	0.02×	▼ 38%
Interest coverage	-61.92×	-4467.76×	-3608.87×	-304.71×	-358.08×	▼ 18%

RXRX price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity

Drawback: less profitable than most peersless profitable than peers

Drawback: growing more slowly than most peersgrowing more slowly than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: its share price swings more than most peers’ (beta 1.07 vs a peer median of 0.63)bigger price swings (beta 1.07 vs peers 0.63)

Ranks #1,063 of 1,157 healthcare companies (bottom 9%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 180% from December 2022 to July 2026.

Recursion Pharmaceuticals had 180% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Recursion Pharmaceuticals had 180% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Stock-based pay is a large cost. Stock pay was 149% of revenue in 2025.

Recursion Pharmaceuticals paid employees $111M in stock in 2025, 149% of its $75M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Recursion Pharmaceuticals looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to June 2026.

Recursion Pharmaceuticals reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Questions investors ask about Recursion Pharmaceuticals

Is Recursion Pharmaceuticals getting weaker?

Its latest SEC filing (Aug 5, 2026) got weaker in some ways: 12-month revenue fell 17.4%. Its overall score is unchanged at 24/100 since Oct 28, 2026.

How is Recursion Pharmaceuticals valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -26.3% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -26.3% vs peers 1.5% (weaker than 100% of peers).

Is Recursion Pharmaceuticals growing?

More slowly than most of its peers. Growth scores 17/100 against 1,393 healthcare peers. Revenue growth -15.1% vs a peer median of 6.1% (weaker than 88% of peers).Revenue growth -15.1% vs peers 6.1% (weaker than 88% of peers).

How profitable is Recursion Pharmaceuticals?

Less profitable than most of its peers. Profitability scores 3/100 against 1,393 healthcare peers. Operating margin -991.7% vs a peer median of 7.1% (weaker than 100% of peers).Operating margin -991.7% vs peers 7.1% (weaker than 100% of peers).

How risky is Recursion Pharmaceuticals?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.02× vs a peer median of 0.22× (stronger than 87% of peers).Debt / equity 0.02× vs peers 0.22× (stronger than 87% of peers). Beta 1.07 vs a peer median of 0.63 (weaker than 74% of peers).Beta 1.07 vs peers 0.63 (weaker than 74% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

66.4M USD

54.9M USD

−17.4%

Net income (12 months)

−559.8M USD

−518.9M USD

−7.3%

Operating margin

-881.3%

-991.7%

−110.4 pts

Free cash flow (12 months)

−325.8M USD

−352.3M USD

+8.1%

Debt

16.4M USD

14.2M USD

−13.7%

Cash

654.5M USD

545.7M USD

−16.6%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

100.0%

-21.2%

4.5%

23.1%

5.0%

▼ 18 pts

Operating margin

-1795.8%

-616.7%

-785.3%

-814.1%

-867.9%

▼ 54 pts

Net margin

-1832.2%

-601.0%

-736.0%

-788.0%

-863.4%

▼ 75 pts

Return on assets (ROA)

-30.6%

-34.1%

-50.2%

-32.0%

-43.7%

▼ 12 pts

Return on equity (ROE)

-34.3%

-49.3%

-70.8%

-44.8%

-57.0%

▼ 12 pts

Free cash flow margin

-1949.4%

-302.6%

-672.4%

-633.7%

-506.5%

▲ 127 pts

Current ratio

11.46×

5.68×

4.70×

3.81×

5.50×

▲ 44%

Debt to equity

0.00×

0.03×

0.02×

▼ 38%

Interest coverage

-61.92×

-4467.76×

-3608.87×

-304.71×

-358.08×

▼ 18%